KKR to take Integer private for $5.7B

KKR to take Integer private for $5.7B is a pharma and life sciences industry update from MedTech Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Elise Reuter · 2026-08-03

Integer expects to gain flexibility and capital to invest in its contract development and manufacturing business under KKR.

Source: MedTech Dive